Epirubicin Market is expected to reach US$ 243.99 Million by 2028

50mg/Vial Segment to Lead Epirubicin Market During 2022–2028

According to our latest study, "Epirubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Dosage, Application, and Distribution Channel," the market was valued at US$ 191.66 million in 2021 and is projected to reach US$ 243.99 million by 2028; it is estimated to grow at a CAGR of 3.60% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments. The growth of the epirubicin market is primarily attributed to rising prevalence of cancer and increasing awareness about cancer. However, the elevated risk of adverse effects due to epirubicin is hampering the market's growth.

Companies engaging in the epirubicin market witnessed a negative impact on their services in early 2020 due to the temporary shutdown of their manufacturing sites caused by the COVID-19 pandemic. Most service providers prioritized actions to help the critical work of consumers included in COVID-19, such as giving a range of high-quality COVID-19-related research tools, reassigning R&D resources for producing essential products for COVID-19, expanding the supply chain, providing flexibility to support expanded demand for enduring products applied for COVID-19 research, and entering into discussions and collaborations across the UK, the US, and China concentrated on SARS-CoV-2 diagnostics, drugs, and vaccines development. According to the European Journal of Oncology Pharmacy, 29% of hospital pharmacists reported shortages of drugs necessary for treating COVID-19 patients, and almost 50% also faced shortages of drugs necessary for treating cancer patients. In addition, most hospital pharmacists reported a decrease in planned surgery for oncology patients and a decrease in the number of chemotherapy preparations.

Based on dosage, the epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. In 2021, the 50mg/vial segment held the largest market share; however, the 100mg/Vial segment is estimated to grow at the fastest CAGR of 4.1% during the forecast period. The largest share of the 50mg/vial segment can be attributed to the rise in cancer cases globally. According to the World Health Organization (WHO), in 2020, 2.3 million women were diagnosed with breast cancer and 685,000 total deaths globally. As of the end of 2020, there were 7.8 million women alive diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. According to the Centers for Disease Control and Prevention (CDC), every year in the US, ~2,64,000 breast cancer cases are diagnosed in women and ~2,400 in men. It is also estimated that ~42,000 women and ~500 men in the US die each year from breast cancer. The Canadian cancer society estimated that in 2022, ~28,600 Canadian women would be diagnosed with breast cancer, and ~5,500 Canadian women would die from breast cancer. Further, it is estimated that in 2022, ~270 Canadian men would be diagnosed with breast cancer, of which 55 men would die due to breast cancer. Further, as per BLADDER CANCER CANADA, in Canada, bladder cancer is the fifth most common cancer, fourth most common in men, and eighth most common in women. It has been estimated that every year ~12,500 Canadians are diagnosed with bladder cancer.

Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd. are among the leading companies operating in the epirubicin market.

Epirubicin Market, by Geography, 2022 (%)

The report segments the epirubicin market as follows:

Based on dosage, the epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. Based on application, the market is segmented into breast cancer, liver cancer, bladder cancer, and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com